✦ LIBER ✦

Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials

✍ Scribed by D. Bilton; G. Canny; S. Conway; S. Dumcius; L. Hjelte; M. Proesmans; B. Tümmler; V. Vavrova; K. De Boeck

Book ID: 118642915
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 99 KB
Volume: 10
Category: Article
ISSN: 1569-1993
DOI: 10.1016/s1569-1993(11)60012-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Research outcomes and recommendations fo

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group

✍ A.M. Stone; W. Bushnell; J. Denne; D.J. Sargent; O. Amit; C. Chen; R. Bailey-Iac 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 327 KB

Proposed outcome measures for prospectiv

Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis–associated uveitis: A consensus effort from the multinational interdisciplinary working group for uveitis in childhood

✍ Arnd Heiligenhaus; Ivan Foeldvari; Clive Edelsten; Justine R. Smith; Rotraud K. 📂 Article 📅 2012 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 87 KB

Recommendations for including multiple s

Recommendations for including multiple symptoms as endpoints in cancer clinical trials : A report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force

✍ Charles S. Cleeland; Jeff A. Sloan; David Cella; Connie Chen; Amylou C. Dueck; N 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

French gene therapy group reports on the

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) : Position statement from the European Society of Gene Therapy (ESGT)

📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

## Position statement from the European Society of Gene Therapy (ESGT) Background News of a serious adverse event in a clinical trial of gene therapy for inherited, X chromosome-linked Severe Combined Immunodeficiency (X-SCID) was made public on October 2, 2002, by the group of French scientists p